Bayer in women's health
For almost a century, Bayer has been working to make a positive difference to women’s health through pioneering research and innovation.
In the 1920s, Bayer—then called Schering AG—made a significant contribution to understanding the molecular structure of sex hormones and launched the world's first oestrogen preparation for menopause management. This firmly set Bayer as a pioneer in women’s healthcare and, in 1961, Bayer became the first company to launch a contraceptive pill in Europe, the combined oral contraceptive Anovlar® (norethisterone acetate/ethinylestradiol)1
More recent innovations include the introduction of Kyleena® (19.5 mg intrauterine delivery system levonorgestrel) a low-dose, levonorgestrel-releasing intrauterine delivery system which was launched in Ireland in 2017.2
- Pletzer BA and Kerschbaum HH. Front Neurosci 2014;8:256. Return to content
- Bayer Ltd. Kyleena® Summary of Product Characteristics Return to content
Just like you, we care about women’s health…
In the 1960s, we were one of the first to launch the contraceptive pill in Europe, giving women more power to choose their own future. Today, we continue to work with women and their clinicians to understand what really matters and where our expertise can help.
You’re a lifelong learner.
So are we.
Whether you want to master new procedures or join the conversation driving innovation in women’s health, we can help.
You care about delivering the best care. So do we.
We’re always looking for ways to help you to help your patients. At Bayer, we’re beside you all the way.
Bayer’s innovations in women’s health timeline:
1960s
First European birth control pill, the combined oral contraceptive Anovlar®* (norethisterone/ethinyl estradiol)
Progestogen-only pill (mini-pill)
First levonorgestrel-releasing IUS, Mirena® (52 mg intrauterine delivery system), launched in Ireland in 1998. Mirena® Prescribing Information
First progestogen-only emergency contraception, Levonelle®* (levonorgestrel) launched in Ireland in 2006
First pill to treat premenstrual dysphoric disorder, a severe form of premenstrual syndrome, in the US for women who choose the contraceptive pill for birth control
First oral contraceptive pill to contain the oestrogen estradiol valerate, an oestrogen that is immediately converted to estradiol in a woman’s body, Qlaira® (estradiol valerate/dienogest) launched in Ireland in 20094. Qlaira® Prescribing Information
First birth control pill approved for the treatment of heavy menstrual bleeding, Qlaira®
Jaydess®▼ (13.5 mg intrauterine delivery system levonorgestrel) launched in Ireland in 2014. Jaydess® Prescribing Information
Kyleena® (19.5 mg intrauterine delivery system levonorgestrel), a low-dose levonorgestrel-releasing IUS launched in Ireland in 2017. Kyleena® Prescribing Information
Present day
- Bayer Ltd. Yasmin Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/yasmin-0-03-mg-3mg-film-coated-tablets-34273/spc. Return to content
- Bayer Ltd. Yasminelle Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/yasminelle-34274/spc. Return to content
- Bayer Ltd. Yaz Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/yaz-0-02mg-3mg-film-coated-tablets-34275/spc. Return to content
- Bayer Ltd. Qlaira, film-coated tablets: Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/qlaira-film-coated-tablets-33497/spc. Return to content
- This product is no longer available. Return to content
Bayer offers a number of contraception methods for women, depending on their personal needs. These include:
Kyleena®
19.5 mg Intrauterine delivery system levonorgestrel
is an IUS indicated for contraceptive use for up to 5 years2
Mirena®
52 mg levonorgestrel-releasing intrauterine system
is an IUS for contraceptive use for up to 8 years, as a treatment option for idiopathic menorrhagia for up to 5 years (If symptoms have not returned after 5 years of use, continued use of the system may be considered. Mirena should be removed or replaced after 8 years at the latest.) and as a protection from endometrial hyperplasia during oestrogen replacement therapy for up to 5 years1
- Bayer Ltd. Mirena® (52 mg intrauterine delivery system levonorgestrel): Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/mirena-52mg-intrauterine-delivery-system-32902/spc Return to content
- Bayer Ltd. Kyleena® (19.5 mg intrauterine delivery system levonorgestrel): Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/kyleena-19-5-mg-intrauterine-delivery-system-32621/spc Return to content
Recommendations
Reporting adverse events and quality complaints
If you want to report a side effect or quality complaint, please contact your health care professional (e.g. physician or pharmacist) or The Health Products Regulatory Authority, Reports can also be reported directly to Bayer through this link or by emailing directly on adr-reland@bayerhealthcare.com
